HeartFlow, Inc

HeartFlow, Inc is a biotechnology and health care startup dedicated to revolutionizing the diagnosis and treatment of cardiovascular disease. Through their innovative HeartFlow Analysis, the company provides a non-invasive personalized cardiac test that empowers physicians to make informed care decisions for patients with suspected coronary artery disease. Having secured approvals for its use in the United States, Canada, Europe, and Japan, and with operational bases in Redwood City, Austin, London, and Japan, HeartFlow is rapidly expanding its presence on a global scale. With a strong financial foundation, HeartFlow recently closed a $215 million Series F investment round, bringing its total funding to over $240 million. Its impressive list of investors for this round includes US Venture Partners, Capricorn Investment Group, Wellington Management, Baillie Gifford, HealthCor Innovations, Janus Handerson, Martis Capital, Hayfin Capital Management, and Bain Capital Life Sciences. Notably, the company is on a pre-IPO trajectory and is leveraging cutting-edge technologies such as deep learning and computational fluid dynamics to advance cardiovascular care. HeartFlow's mission extends beyond technology, as it strives to integrate the best practices of both technology and healthcare companies. The company's commitment to hiring individuals passionate about their mission of saving lives, improving the patient experience, and reducing the overall cost of care reflects its dedication to making a meaningful impact in the medical field. For more details, interested stakeholders can visit www.heartflow.com.